Monthly haemostatic factor variability in women and men

Hormonal status influences haemostatic factors including fibrinogen, factor VII and plasminogen activator inhibitor (PAI‐1), and concentrations differ among men, premenopausal and postmenopausal women. This study examines how phases of the menstrual cycle influence variability of fibrinogen, factor VII and PAI‐1.

[1]  I. Milsom,et al.  Hormonal contraception and venous thromboembolism , 2012, Acta obstetricia et gynecologica Scandinavica.

[2]  H. Kluin-Nelemans,et al.  Haemostatic variables during normal menstrual cycle , 2011, Thrombosis and Haemostasis.

[3]  P. Kouides,et al.  Hormonal influences on hemostasis in women. , 2011, Seminars in thrombosis and hemostasis.

[4]  D. Moher,et al.  A catalogue of reporting guidelines for health research , 2010, European journal of clinical investigation.

[5]  Xianggui Qu,et al.  Linear Model Theory: Univariate, Multivariate, and Mixed Models , 2007, Technometrics.

[6]  M. Cushman.  Epidemiology and risk factors for venous thrombosis. , 2007, Seminars in hematology.

[7]  S. Koh,et al.  Hemostatic Status and Fibrinolytic Response Potential at Different Phases of the Menstrual Cycle , 2005, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[8]  L. Rabbani,et al.  Dynamic variability of hemostatic and fibrinolytic factors in young women. , 2004, The Journal of clinical endocrinology and metabolism.

[9]  P. Ridker,et al.  Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. , 2004, Circulation.

[10]  C. Borgfeldt,et al.  Low-dose oral combination of 17β-estradiol and norethisterone acetate in postmenopausal women decreases factor VII, fibrinogen, antithrombin and plasminogen activator inhibitor-1 , 2004, Climacteric : the journal of the International Menopause Society.

[11]  Joon-Oh Park,et al.  Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients , 1998, Breast Cancer Research and Treatment.

[12]  P. Kris-Etherton,et al.  Variation of lipids and lipoproteins in premenopausal women compared with men and postmenopausal women. DELTA (Dietary Effects on Lipoproteins and Thrombogenic Activity) Investigators. , 2000, Metabolism: clinical and experimental.

[13]  L. Weinehall,et al.  High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. , 1998, Circulation.

[14]  H. Eichler,et al.  Plasma Levels of Activated Factor VII Decrease during the Menstrual Cycle , 1998, Thrombosis and Haemostasis.

[15]  P. Kris-Etherton,et al.  Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[16]  D. Gordon,et al.  ApoE genotype does not predict lipid response to changes in dietary saturated fatty acids in a heterogeneous normolipidemic population. The DELTA Research Group. Dietary Effects on Lipoproteins and Thrombogenic Activity. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[17]  M. Blombäck,et al.  Prediction of Changes in Levels of Haemostatic Variables during Natural Menstrual Cycle and Ovarian Hyperstimulation , 1997, Thrombosis and Haemostasis.

[18]  S. Thompson,et al.  Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. , 1996, Circulation.

[19]  M. Cushman,et al.  Laboratory methods and quality assurance in the Cardiovascular Health Study. , 1995, Clinical chemistry.

[20]  H. Ginsberg.  New directions in dietary studies and heart disease: the National Heart, Lung and Blood Institute sponsored Multicenter Study of Diet Effects on Lipoproteins and Thrombogenic Activity. , 1995, Advances in experimental medicine and biology.

[21]  P. Marckmann,et al.  The variability of and associations between measures of blood coagulation, fibrinolysis and blood lipids. , 1992, Atherosclerosis.

[22]  I. Godsland,et al.  The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. , 1990, The New England journal of medicine.

[23]  L. Lissner,et al.  Variation in energy intake during the menstrual cycle: implications for food-intake research. , 1988, The American journal of clinical nutrition.

[24]  M. Alessi,et al.  Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. , 1988, Blood.

[25]  J. Griffin,et al.  Evidence for the participation of both activated factor XII and activated factor IX in cold-promoted activation of factor VII. , 1978, Thrombosis research.

[26]  A. Clauss.  [Rapid physiological coagulation method in determination of fibrinogen]. , 1957, Acta haematologica.